Novo Nordisk's Wegovy subscription plan could expand access and influence pricing dynamics in the GLP-1 obesity-drug market

Over the past two years, Novo Nordisk has lost its lead in the anti-obesity market to Eli Lilly. The Denmark-based pharmaceutical company has responded with new drug launches, label expansions for Wegovy, and efforts to improve access to its weight management medicine. One recent move—offering longer Wegovy prescription subscriptions—could help broaden the market and support future growth.

Underpenetration of GLP-1s and the access challenge

Despite the popularity of GLP-1 drugs, many patients who could benefit are not currently taking them. Using the standard U.S. definition of obesity as a body mass index (BMI) of 30 or higher, about 40.3% of U.S. adults were obese a few years ago. However, BMI does not distinguish between visceral fat (stored in the abdomen and more dangerous) and subcutaneous fat, nor does it differentiate between muscle and fat.

Because of these limitations, some researchers have estimated obesity prevalence in the U.S. could be closer to 70%. Even with that broader view, adoption remains limited: as of last year, only 12% of people in the U.S. were on GLP-1s, and about 18% had ever taken these drugs.

Wegovy subscription plan for three, six, or 12 months

Novo Nordisk’s recent initiative aims to address pricing and access for cash-paying patients. The company announced Wegovy prescriptions available for three, six, or 12 months. Patients can arrange these longer prescriptions through telehealth platforms, with savings increasing the longer the subscription period.

Market impact and competitive context

The subscription model could help Novo Nordisk reach significantly more patients in a market that remains underpenetrated. While the approach may not be enough to immediately restore leadership versus Eli Lilly—particularly if Eli Lilly adjusts its pricing—Novo Nordisk’s broader strategy may still support its position.

The company’s longer-term prospects also depend on its pipeline. The article notes that Novo Nordisk is working on newer medicines, including treatments targeted at patients at even higher risk, which could carry stronger pricing power. Pipeline progress could help the company “bounce back” over the next few years.

Investor snapshot and valuation

Novo Nordisk is trading at 11x forward earnings, compared with an average of 17.3x for healthcare stocks, according to the article. The stock data provided includes a current price of $36.98, a market capitalization of $125B, a gross margin of 80.90%, and a dividend yield of 4.87%.

• NYSE ticker: NVO
• Current price: $36.98
• Day’s range: $35.63 - $36.98
• 52-week range: $35.12 - $81.44
• Volume: 15M (Avg vol: 24M)
• Gross margin: 80.90%
• Dividend yield: 4.87%

Overall, the article concludes that Novo Nordisk appears positioned to benefit from improved access while investors consider the stock at a discount to broader healthcare valuation multiples.